Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT

This study has been completed.
Information provided by:
Benaroya Research Institute Identifier:
First received: September 25, 2008
Last updated: May 25, 2010
Last verified: May 2010
This study is being conducted to find out what effects (good and bad) that a combination of treatment with chemotherapy, radiation therapy and surgery has on you and your pancreatic cancer. The chemotherapy drugs to be used: Gemcitabine, Docetaxel, Oxaliplatin, 5-FU and alpha-interferon. The goal is to decrease the size of the tumor, so that removal by surgery can be performed. Current treatments for this stage of pancreas cancer offer less than ideal results, with little opportunity for treatment with curative intent.

Condition Intervention Phase
Pancreatic Cancer
Drug: Gemcitabine, Docetaxel, 5FU, Oxaliplatin
Biological: Alpha-interferon
Radiation: Abdominal/pelvic radiation therapy
Procedure: Pancreaticoduodenectomy
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Protocol in Borderline Resectable Pancreatic Cancer Using Gemcitabine/Docetaxel Chemotherapy and An Oxaliplatin-Based Chemoradiation.

Resource links provided by NLM:

Further study details as provided by Benaroya Research Institute:

Primary Outcome Measures:
  • Two year overall survival [ Time Frame: two years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • median disease free survival initial response rate to gemcitabine/docetaxel (tumor marker and radiographic) toxicity of overall regimen time to disease progression percentage of patients able to complete protocol to entirety [ Time Frame: two years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 40
Study Start Date: September 2008
Study Completion Date: April 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Gemcitabine, Docetaxel, 5FU, Oxaliplatin
    Gemcitabine: 1000 mg/m2 IV bolus days 1 and 8, repeated every 21 days x 8cycles Docetaxel: 40 mg/m2 IV bolus days 1 and 8, repeated every 21 days x 8 cycles Gemcitabine/docetaxel will be repeated (based upon initial response) Oxaliplatin: 40 mg/m2 IV on day 1 of each week of radiation 5-FU: 175 mg/m2 continuous infusion on days 1-18 and 29-46 of radiation
    Biological: Alpha-interferon
    Alpha-interferon: injected subcutaneously on days 1, 3, 5, 8, 10, 12, 15, 17, 29, 31, 33, 36, 38, 40, 43 and 46 during radiation therapy
    Radiation: Abdominal/pelvic radiation therapy
    3-D conformal technique. The dose per fraction will be 180cGy, with a total dose of 5040 cGy in 28 fractions. Radiation therapy will be delivered on days 1-18 and days 29-46
    Procedure: Pancreaticoduodenectomy
    Surgery performed if subject is considered candidate by protocol definition.
Detailed Description:

Subjects must have biopsy proven adenocarcinoma of the pancreas which is bidimensionally measurable on CT. Cancer must be considered locally advanced (not able to be treated surgically). Subjects must not have received prior treatment for pancreatic cancer. Subjects must not have received prior radiation therapy to the abdomen or pelvis (for any reason). Subjects cannot be receiving immunosuppressive therapy (e.g. prednisone, methotrexate). Eligible subjects will receive initial chemotherapy regimen to include eight cycles of Gemcitabine and Docetaxel. All subjects will be re-evaluated for surgery - if tumor has shrunk enough, subject will undergo surgery, followed by additional chemotherapy of Oxaliplatin, 5FU and Alpha-interferon and radiation therapy; once subject has recovered from side effects of the chemo/radiation therapy, they will receive a final chemotherapy regimen of four cycles of Gemcitabine and docetaxel. Subjects who are not surgical candidates after eight cycles of chemotherapy will undergo an additional four cycles of Gemcitabine and docetaxel followed by reassessment for surgery. If they are a surgical candidate, they will undergo surgery followed by chemo/radiation therapy regimen. If they are not a surgical candidate, they will undergo the chemo/radiation therapy regimen.

Subjects may be removed from the study treatment for the following reasons:

  • The investigator feels the subject is not benefitting from treatment
  • The subject chooses to discontinue for any reason
  • The subject experiences side effects which are considered to be unacceptable
  • The subject has an increase in the size of their tumor

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Biopsy proven adenocarcinoma of the pancreas
  • Tumor must be radiographically bidimensional by abdominal/pelvic CT
  • Cancer must be locally advanced and not considered immediately treated by standard surgical procedure
  • No prior therapy for pancreas cancer

Exclusion Criteria:

  • Women who are pregnant or lactating
  • Subjects who have received prior external beam radiation to the abdomen or pelvis
  • Subjects receiving chronic immunosuppressive therapy (prednisone, methotrexate)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00761241

United States, Washington
Virginia Mason Medical Center
Seattle, Washington, United States, 98101
Sponsors and Collaborators
Benaroya Research Institute
Principal Investigator: Vincent Picozzi, MD Virginia Mason Medical Center
  More Information

Responsible Party: Vincent Picozzi, MD/Principal Investigator, Virginia Mason Medical Center Identifier: NCT00761241     History of Changes
Other Study ID Numbers: IRB07124  IST14087 
Study First Received: September 25, 2008
Last Updated: May 25, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by Benaroya Research Institute:
pancreas cancer
combined modality therapy

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Neoplasms by Site
Pancreatic Diseases
Anti-Infective Agents
Antimetabolites, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Tubulin Modulators processed this record on April 27, 2016